TERT and neoplasm: Single TERT promoter variants, BRAFV600E or RAS mutations and TERT promoter mutations or TP53 inactivating mutations co-mutations will reduce progression-free survival and are highly associated with aggressive tumor cells and a high rate of recurrence (6, 10, 14–16).